Search Results

ASP Isotopes PET Lab Revenue Grows Over 50% in First Half of Year, Isotope Enrichment Facilities Advance Toward Commercial Production

ASP Isotopes Inc. recently released a letter to shareholders outlining operational progress across its business segments ahead of the company's second-quarter 2026 financial results announcement. The company stated that its PET lab segment achieved organic revenue growth of more than 50% in the first half of 2026 compared to the same period in 2025. Based on current expectations, the segment's full-year 2026 revenue is projected to be approximately $14 million, up from $6 million in 2025. PET-related operations are typically closely associated with radiopharmaceutical preparation, molecular imaging, and nuclear medicine diagnostic applications. On the isotope front, ASP Isotopes stated that its silicon-28 and ytterbium-176 enrichment facilities have entered the final stage before commercial production, with first deliveries expected in the second half of 2026...

2026-08-05

BWXT to Sell Medical Business to Nordic Capital for Up to $800 Million

On August 3, BWX Technologies, Inc. announced that it has reached a definitive agreement to sell its medical business to healthcare investment company Nordic Capital. The transaction is valued at up to $800 million and includes BWXT Medical and the stable medical isotope business of Kinectrics. BWXT stated that the divestiture will help the company concentrate resources and capital to drive growth in its core nuclear national security business and commercial nuclear power market operations. The company believes these areas are its long-term strategic priorities. Under Nordic Capital's ownership, the medical business is expected to further expand its scale, enhance capabilities, and strengthen its position in the radiopharmaceutical field...

2026-08-04

Curium and Lantheus Reach Definitive Merger Agreement to Build a Global Integrated Radiopharmaceutical Theranostics Platform

On August 3, global radiopharmaceutical company Curium announced that it has entered into a definitive merger agreement with Lantheus Holdings, Inc. Under the agreement, Curium US Holdings LLC will merge with Lantheus through its wholly owned subsidiary, with a total consideration of up to $114.50 per share and a total transaction value of approximately $8 billion. Under the terms of the agreement, Curium US will acquire all outstanding shares of Lantheus at $102.50 per share in cash upon closing of the transaction. In addition, Lantheus shareholders will receive non-transferable contingent value rights, entitling them to up to $12.00 per share in additional cash payments if certain commercial milestones for Lantheus-related products are achieved by 2030...

2026-08-04

UT-ORNL Recruits Radiopharmaceutical Scientist to Advance Integrated Cancer Diagnosis and Treatment

The University of Tennessee and Oak Ridge National Laboratory jointly announced that Dr. Carolyn Anderson has been appointed to the UT-ORNL Governor's Chair in Nuclear Medicine: Radiopharmaceutical Therapy. Anderson officially assumed the position on August 1, serving concurrently as a professor in the Department of Nuclear Engineering at the University of Tennessee, Knoxville, and as a researcher in the Isotope Science and Enrichment Directorate at Oak Ridge National Laboratory. She is an internationally renowned pioneer in the field of radiopharmaceutical science, having worked at institutions such as the University of Washington, the University of Pittsburgh, and the University of Missouri. Dr. Anderson's research focuses on developing compounds that can identify cancer earlier, assess treatment efficacy, and deliver radiation directly to tumors...

2026-08-04

Guangzhou Taihe Proton Therapy Center Surpasses 1,000 Patients Treated

Since the ProBeam proton radiotherapy system at the Proton Therapy Center of Guangzhou Taihe Cancer Hospital was officially put into clinical use in December 2024, the center has provided proton radiotherapy services to more than 1,000 patients within 19 months, with consecutive single-day treatment volumes exceeding 100 patient sessions. According to information released by the hospital, compared with the time taken by some internationally comparable proton centers to complete 1,000 clinical cases, Guangzhou Taihe took 19 months. Relevant comparisons include: Emory Proton Therapy Center in the United States took 2 years to complete 1,000 cases after launching in December 2018; MIBS Proton Therapy Center in Russia took approximately 2 years after trial operation began in September 2017; University College London Hospitals Proton Centre in the United Kingdom took nearly 4 years after launching in December 2021; Tata Memorial Centre in Mumbai, India, took nearly 3 years after launching in 2023; and the Proton Centre at the National Cancer Centre Singapore took 26 months to complete 500 cases after launching in June 2023.

2026-08-04

Two Joint Laboratories for Radiation Injury Treatment under the Institute of Radiation Medicine, Chinese Academy of Medical Sciences, Inaugurated in Shanghai and Wuxi

From July 30 to 31, Zhou Jiaxi, Director of the Institute of Radiation Medicine, Chinese Academy of Medical Sciences, Liu Qiang, Deputy Director, Su Xu, Distinguished Professor, along with relevant heads from the National Nuclear Radiation Medical Treatment Base (Tianjin), the Science and Technology Department, and the Industry Department, successively visited Shanghai Pulmonary Hospital and the Affiliated Hospital of Jiangnan University for cooperation exchanges, and jointly inaugurated the two joint laboratories for radiation injury treatment. On the afternoon of July 30, the plaque presentation ceremony for the joint laboratory between the Institute of Radiation Medicine and Shanghai Pulmonary Hospital was held in Shanghai. Chen Chang, Deputy Secretary of the Party Committee and President of Shanghai Pulmonary Hospital, Liu Haipeng, Vice President, and heads of relevant departments attended the event. Zhou Jiaxi stated that the co-establishment of the joint laboratory is a...

2026-08-04

Zhongji Flash e-Flash 200A Enters Innovative Medical Device Special Review Program

Recently, the public notice period for the review results of applications for the Innovative Medical Device Special Review Program by the Center for Medical Device Evaluation of the National Medical Products Administration has concluded. The ultra-high dose rate electron beam radiotherapy system (e-Flash 200A), independently developed by Zhongji Flash Medical Technology Co., Ltd., has officially entered the Innovative Medical Device Special Review Program. According to reports, the e-Flash 200A is China's first ultra-high dose rate electron beam FLASH radiotherapy device and had previously been included in the "Global New" green channel. Its entry into the Innovative Medical Device Special Review Program signifies further recognition of the product's technological innovation and clinical application value. The system is designed for superficial tumor radiothe...

2026-08-04

Ratio Therapeutics Completes $70 Million Series C Financing to Advance Clinical Development of Ac-225 Targeted Radiopharmaceuticals

Ratio Therapeutics, Inc., a U.S. clinical-stage pharmaceutical company, recently announced the completion of a $70 million Series C financing round. The company stated that following this round, its cumulative total financing has exceeded $240 million. According to the announcement, this round saw participation from existing investors Duquesne Family Office and Bristol Myers Squibb, while also bringing in new investors such as Catalio Capital Management, Eli Lilly and Company, and Wasatch Group. Ratio Therapeutics stated that the proceeds will be used to advance the clinical development of its targeted radiotherapeutic product pipeline and expand manufacturing infrastructure. The company plans to continue advancing the ATLAS study, which is evaluating its lead radiotherapeutic agent [Ac-2...

2026-08-03

United Imaging Healthcare's New-Generation Digital PET/CT "uMI Panvivo" Enters Clinical Use in Japan

August 3 news, United Imaging Healthcare Japan Co., Ltd. announced that the first unit in Japan of its new-generation digital PET/CT scanner uMI Panvivo has been put into clinical use at Saitama Central Clinic, located in Omiya-ku, Saitama City. Saitama Central Clinic is a medical institution specializing in diagnostic imaging. Since its opening in 2009, the clinic has continuously conducted comprehensive cancer screening centered on PET/CT scans, and provides FDG-PET cancer examination services based on the needs of local medical institutions, with an annual PET/CT examination volume ranking among the highest in Japan. With the introduction of uMI Panvivo, the clinic expects to further shorten examination time and enhance image quality on the basis of its existing high-precision diagnostic imaging...

2026-08-03

The Institute of High Energy Physics of the Chinese Academy of Sciences Successfully Held the Fourth "1+1" Youth Forum on Nuclear and Particle Physics — Frontier Technologies Empowering Nuclear Medicine Diagnosis and Treatment

On July 25, 2026, the fourth "1+1" Youth Forum on Nuclear and Particle Physics (hereinafter referred to as the "1+1 Forum") was successfully held at the Institute of High Energy Physics of the Chinese Academy of Sciences (hereinafter referred to as IHEP). Themed "Frontier Technologies Empowering Nuclear Medicine Diagnosis and Treatment," the forum was organized by the Youth Working Committee of the Beijing Nuclear Society and the IHEP Group of the Youth Innovation Promotion Association of the Chinese Academy of Sciences, co-organized by the Institute of High Energy Physics of the Chinese Academy of Sciences and the School of Nuclear Science and Technology of the University of Chinese Academy of Sciences, and hosted by the R&D Center for Nuclear Technology (Nuclear Detection and Nuclear Imaging) of the China Atomic Energy Authority and the Beijing Engineering Research Center for Radiation Imaging Technology and Equipment. The 1+1 Forum has always adhered to the principle of organically combining demand with technology, academia with science popularization...

2026-08-03

Xinjiang's First Domestically Developed SPECT/CT Put into Operation at the First Affiliated Hospital of Shihezi University

Recently, the mid-term summary meeting of the National Key R&D Program project "Research on Application Solutions for Domestically Developed Dual-Head Single-Photon Imaging Equipment (SPECT)" under the 14th Five-Year Plan, along with the SPECT/CT commissioning ceremony and academic seminar, was held at the First Affiliated Hospital of Shihezi University. The Insight four-dimensional quantitative SPECT/CT from永新医疗 (Yongxin Medical) was officially installed in Xinjiang, becoming the first domestically developed SPECT/CT system put into clinical use in the region. A representative from the First Affiliated Hospital of Shihezi University stated that the commissioning of the domestically developed SPECT/CT will help the hospital improve its precision diagnosis and treatment system in northern Xinjiang and enhance regional nuclear medicine service capabilities. Experts attending the meeting noted that the deployment of this system in clinical practice will help explore the standardized application pathways of SPECT/CT in primary hospitals and accumulate clinical experience in the use of nuclear medicine imaging equipment in western China.

2026-08-03

Curium Advances Second Cyclotron Investment Plan in Romania to Expand PET Imaging Supply

On July 30, Curium announced that it is advancing its second cyclotron investment plan in Romania to expand access to advanced nuclear medicine services locally and further strengthen healthcare infrastructure. According to the introduction, after completing assessments of market opportunities, technical requirements, and regional infrastructure, Curium has identified the Cluj-Napoca region as the preferred site for the project and selected a preferred local partner. Preparatory work is currently underway to support the project's progression to the next phase. This expansion plan aims to increase relevant production capacity, enhance PET imaging equipment and service supply capabilities, improve patient access to advanced diagnostic procedures, and support the...

2026-07-30

Hengyang Deploys Measures to Advance the Development of the Nuclear Technology Application Industry Cluster

On the morning of July 22, Liu Zhongjie, Deputy Secretary of the CPC Hengyang Municipal Committee and Mayor of Hengyang, presided over a special coordination meeting on the development of the nuclear technology application industry to discuss and advance

2026-07-27

Professor Shi Hongcheng was invited to participate in the International Atomic Energy Agency (IAEA)-sponsored tiered clinical skills training program on the integration of nuclear medicine diagnosis a

From July 12 to 17, 2026, a regional training program titled "Graded Clinical Skills Training on Integrated Nuclear Medicine Theranostics," hosted by the International Atomic Energy Agency (IAEA) for member states of the Asian Regional Cooperati

2026-07-27

CNNC-CNI assists in the launch of the high-quality nuclear medicine diagnosis and treatment project at Mianyang Central Hospital.

A high-quality development project for nuclear medicine diagnosis and treatment was recently launched at Mianyang Central Hospital. An expert delegation from the Chinese Society of Nuclear Medicine (CSNM), accompanied by representatives from China Isotope

2026-07-27